neuromuscular blockade does not improve mortality in ARDS

• related: ARDS acute respiratory distress syndrome
• tags: #literature #icu

---

The ACURASYS and ROSE trials evaluated the benefit of early cisatracurium (within the first 48 h) on mortality rates in moderate to severe ARDS (defined as a PaO2:FiO2 ratio of <150 mm Hg). In ACURASYS, early continuous infusion of cisatracurium decreased 90-day mortality compared with placebo (31% vs 42%), but that finding was not replicated in the ROSE trial (42.5% vs 42.8%; P = ). Taken together, it is not clear that routine, early continuous infusion of cisatracurium for 48 h in isolation has a mortality benefit in moderate to severe ARDS.^{1 2}

Links to this note

• ARDS acute respiratory distress syndrome
  • neuromuscular blockade does not improve mortality in ARDS

Footnotes

1. SEEK Questionnaires ↩

2. National Heart, Lung, and Blood Institute PETAL Clinical Trials Network; Moss M, Huang DT, Brower RG, et al. Early neuromuscular blockade in the acute respiratory distress syndrome. N Engl J Med. 2019;380(21):1997-2008. PubMed ↩